Skip to main content
Year archive

Egetis Therapeutics — 2025 filings

All 32 regulatory filings released by Egetis Therapeutics (EGTX) in 2025, sourced directly from the official regulator.

32 Filings
2025 Period
2025 filings (32)
Filing Released Lang
Ändring av antalet stamaktier och röster i Egetis Therapeutics
Share Issue/Capital Change
2025-12-30 Swedish
Change in the number of ordinary shares and votes in Egetis Therapeutics
Share Issue/Capital Change
2025-12-30 English
Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency
Regulatory Filings
2025-12-19 English
Egetis Therapeutics inleder NDA ansökan i USA för Emcitate® (tiratricol) vid MCT8-brist
Regulatory Filings
2025-12-19 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-11-25 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-11-25 English
Egetis meddelar positiva resultat från ReTRIACt-studien med Emcitate® (tiratricol) vid MCT8-brist
Regulatory Filings
2025-11-14 Swedish
Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency
Regulatory Filings
2025-11-14 English
Change in the number of shares and votes in Egetis Therapeutics
Share Issue/Capital Change
2025-10-31 English
Ändring av antalet aktier och röster i Egetis Therapeutics
Share Issue/Capital Change
2025-10-31 Swedish
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) baserat på redan tillgängliga kliniska data
Legal Proceedings Report
2025-10-23 Swedish
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data
Regulatory Filings
2025-10-23 English
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million
Share Issue/Capital Change
2025-10-02 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående till 183 miljoner kronor
Share Issue/Capital Change
2025-10-02 Swedish
Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares
Capital/Financing Update
2025-10-02 English
Egetis Therapeutics avser att genomföra en riktad nyemission av högst 10 procent av utestående stamaktier
Share Issue/Capital Change
2025-10-02 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-21 English
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency
Regulatory Filings
2025-07-15 English
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för behandling av MCT8-brist
Regulatory Filings
2025-07-15 Swedish
Annual Report (ESEF) 2024
Annual Report (ESEF) FY 2024
2025-05-16 Swedish
Kommuniké från Egetis Therapeutics årsstämma 2025
AGM Information
2025-05-06 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
AGM Information
2025-05-06 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-04-30 Swedish
Earnings Release 2025
Earnings Release Q1 2025
2025-04-30 English
Annual Report (ESEF) 2024
Annual Report (ESEF) FY 2024
2025-04-11 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement
2025-04-03 English
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement
2025-04-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report FY 2024
2025-02-26 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report FY 2024
2025-02-26 English
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency
Regulatory Filings
2025-02-13 English
EU-kommissionen godkänner Egetis Emcitate® (tiratricol) som den första och enda behandlingen för patienter med MCT8-brist
Regulatory Filings
2025-02-13 Swedish